I don't know which ASX biotechs you follow - they can't be very promising or have small target markets.
IMU - $450m (Phase II and phase I trials underway) RCE - $182m (Phase I) IBX - $124m (Phase I) IHL - $150m (Phase I/II) NOX - $115m (Phase I/II)
PAR - $573m (Phase III) MSB - $1.35B (Phase III)
Also, a return on investment isn't necessarily years away. This could reach many multiples of the current value by the time early clinical trial results are out, if they are positive. Massive TAMs, clear strategy, promising pre-clinical results.
The early trials will be relatively quick (no long endpints such as survival data or joint mobility/regeneration etc). That's one thing I also like about $RCE - the trail outcomes will be measurable within days-weeks, as opposed to months-years.
I've bought a small parcel now and will top up occasionally.
NYR Price at posting:
23.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)